June 6, 2006 – Human Genome Sciences signed a $507.5 million deal with Novartis to develop Albuferon; ImClone sold off after studies showed Erbitux was not as powerful as expected; Gilead will pay 115.2 million euros to buy the Raylo Chemicals unit of Degussa; Xechem was awarded Orphan Drug Designation for a sickle cell disease compound; Aspreva and Roche received Orphan Drug Designation for CellCept; and Wyeth and Progenics will develop three forms of its drug for the side effects of opioids. The Centient Biotech 200™ closed 16 points lower at 3637.11, a drop of .43%. More details...
